Anti-Human CTLA-4 Reference Antibody (ADU-1604, RUO) (HB651126)

Name: Anti-Human CTLA-4 Reference Antibody (ADU-1604, RUO)
Brand: abinScience
SKU: HB651126
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HB651126
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	ADU-1604
Activité biologique	ADU-1604 (30 mg/kg, i.v., once a week for 5 weeks) is well tolerated in cynomolgus monkeys [2]. ADU-1604 demonstrates comparable anti-tumor efficacy to a reference antibody upon systemic administration and following intertumoral injection in humanized non-small cell lung cancer (NSCLC) PDX models [2].
Cible	CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P16410
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	ADU-1604, ADU1604, ADU1604
Contexte	Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy). 1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501 2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244 4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933 5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304 6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017
Reférences	1. Velasco G D, et al. ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma. 2024. [HB651126] 2. Maaike Hendriks, et al. Abstract 1702: Assessment of pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in non-human primates and evaluation of local anti-CTLA-4 application. 2018. Volume 78, issue 13 [HB651126]
Note	For research use only. Not suitable for clinical or therapeutic use.